Uptake of Cis-4-[18F]Fluoro-l-Proline in Urologic Tumors

Journal of Nuclear Medicine

Hans Herzog¹  Heinz H. Coenen¹  Kurt Hamacher¹  Karl-Josef Langen¹  Volker Müller-Mattheis¹  Rolf Ackermann¹  Anne Rose Börner¹ 

[1] Institutes of Medicine and Nuclear Chemistry, Research Center Jülich, Jülich; and Clinics of Nuclear Medicine and Urology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany Institutes of Medicine and Nuclear Chemistry, Research Center Jülich, Jülich; and Clinics of Nuclear Medicine and Urology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany Institutes of Medicine and Nuclear Chemistry, Research Center Jülich, Jülich; and Clinics of Nuclear Medicine and Urology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany

关键词: cis-4-[¹⁸F]fluoro-l-proline;    radiolabeled amino acids;    renal tumors;    PET;   

DOI  :  

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Tumor uptake of the amino acid cis-4-[18F]fluoro-l-proline (cis-FPro) was studied with PET in eight patients with urologic tumors. Methods: Three patients had primary renal cell carcinomas (RCCs), one had a local recurrence of RCC, one had squamous RCC, one had an adrenal hemangioma, one had inguinal metastases of penile squamous carcinoma, and one had suspected metastatic disease from prostate cancer. PET scans of the trunk were acquired at 1 and 3–5 h after intravenous injection of 400 MBq cis-FPro and compared with 18F-FDG PET scans and CT. Results: None of the tumors or metastases showed significant uptake of cis-FPro. FDG uptake was seen in one of the three primary RCCs, in the local recurrence of RCC, in the squamous RCC, and in the metastases of penile cancer. Conclusion: Cis-FPro appears not to be a promising PET tracer in oncology.

【 授权许可】

Unknown